Roche/GSK Boniva Once-Monthly To Be Launched In April
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies are planning "substantial" DTC ad campaigns, Roche says. FDA approves supplemental NDA for once-monthly ibandronate for treatment of osteoporosis in postmenopausal women. Boniva will be priced competitively to the currently marketed bisphosphonates, Roche says.
You may also be interested in...
Bisphosphonate Marketers Push Dosing Advantages After Feb. 6 Fosamax Patent Expiry
Branded osteoporosis drug makers gird for a hit from launch of a low-cost version of Merck’s market leading alendronate.
Bisphosphonate Marketers Push Dosing Advantages After Feb. 6 Fosamax Patent Expiry
Branded osteoporosis drug makers gird for a hit from launch of a low-cost version of Merck’s market leading alendronate.
Roche Plans Boniva Ad Changes To Energize “Static” Script Growth
Swiss drug maker’s new strategy for the osteoporosis therapy will include Fosamax comparison data, new spokesperson.